These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 23154591

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension.
    Watanabe S, Okura T, Kurata M, Irita J, Manabe S, Miyoshi K, Fukuoka T, Gotoh A, Uchida K, Higaki J.
    Clin Exp Hypertens; 2006 Jul; 28(5):451-61. PubMed ID: 16820342
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C, VIVALDI investigators.
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [Abstract] [Full Text] [Related]

  • 5. The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.
    Yanagi M, Tamura K, Fujikawa T, Wakui H, Kanaoka T, Ohsawa M, Azushima K, Maeda A, Kobori H, Umemura S.
    Hypertens Res; 2013 Mar; 36(3):262-9. PubMed ID: 23154587
    [Abstract] [Full Text] [Related]

  • 6. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
    Moniwa N, Varagic J, Ahmad S, VonCannon JL, Simington SW, Wang H, Groban L, Brosnihan KB, Nagata S, Kato J, Kitamura K, Gomez RA, Lopez ML, Ferrario CM.
    Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
    [Abstract] [Full Text] [Related]

  • 7. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial.
    Narumi H, Takano H, Shindo S, Fujita M, Mizuma H, Kuwabara Y, Komuro I, Valsartan Amlodipine Randomized Trial Investigators.
    Hypertens Res; 2011 Jan; 34(1):62-9. PubMed ID: 20927112
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL, Ekhlas A, Nguyen JM, Moranne O.
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [Abstract] [Full Text] [Related]

  • 10. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD.
    Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H.
    Am J Kidney Dis; 2004 Jun; 43(6):1056-64. PubMed ID: 15168386
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease.
    Mochizuki S, Shimizu M, Taniguchi I, Kanae K, Yoshida S, Tajima N, Dahlöf B, JIKEI HEART Study Group.
    Cardiovasc Drugs Ther; 2004 Jul; 18(4):305-9. PubMed ID: 15367828
    [Abstract] [Full Text] [Related]

  • 14. Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.
    Saito I, Kushiro T, Zenimura N, Matsushita Y, Sagawa K, Hiramatsu K, Yamaguchi F.
    J Nephrol; 2012 Jul; 25(5):699-708. PubMed ID: 22020401
    [Abstract] [Full Text] [Related]

  • 15. Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
    Takano H, Hasegawa H, Narumi H, Shindo S, Mizuma H, Kuwabara Y, Kobayashi Y, Komuro I, VART investigators.
    J Hum Hypertens; 2012 Nov; 26(11):656-63. PubMed ID: 21993491
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases.
    Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Ando N, Ohta S, Yoshii M, Inada H, Tsukada K, Minami J, Ono H, Matsuoka H.
    Hypertens Res; 2005 Nov; 28(11):865-70. PubMed ID: 16555574
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
    Andrés A, Morales E, Morales JM, Bosch I, Campo C, Ruilope LM, Valsartan in Renal Transplantation Group.
    Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
    [Abstract] [Full Text] [Related]

  • 19. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 20. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.
    Yilmaz MI, Carrero JJ, Martín-Ventura JL, Sonmez A, Saglam M, Celik T, Yaman H, Yenicesu M, Eyileten T, Moreno JA, Egido J, Blanco-Colio LM.
    Clin J Am Soc Nephrol; 2010 Jul 20; 5(7):1174-81. PubMed ID: 20430947
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.